(67 osseous, 1 liver, and 3 lymph node). Of these, 65 lesions were visible on the standard of care imaging (CT and/or bone scan). One PET-avid osseous vertebral body metastasis was not apparent on either CT or bone scan. Twenty-five lesions were not PET-avid but seen on CT and bone scan (17 bone, 6 lymph node, 1 pleural, and 1 liver). The average of the maximum SUVs for bone or soft tissue metastases for patients treated at higher doses and uptake time was statistically higher than the corresponding parameter in normal liver, muscle, and bone. Visually obvious blood pool activity was observed even 3-4 h post injection, suggesting that further optimization of the [ 68 Ga]citrate imaging protocol is required to maximize signal-to-background ratios. 
Introduction
Despite intense research efforts, there are relatively few nuclear imaging tools that effectively detect prostate cancer. 11 C]choline, a radiotracer for PET that targets prostate cancer tumor cells [1, 2] .
All have recognized limitations. For instance, metabolic bone imaging agents are not specific for the microenvironment around osseous prostate cancer lesions and will detect bone remodeling due to non-malignant pathologies (e.g., microfractures). Moreover, they do not detect soft tissue lesions, limiting its application in the substantial number of advanced prostate cancer patients with predominantly soft tissue/visceral metastases. Using bone scans to monitor the response of advanced prostate adenocarcinoma to systemic therapies is challenging because bone remodeling can persist for weeks or even months after ablation of the nearby tumor. [ 11 C]choline was recently approved for the detection of occult prostate cancer lesions in post-prostatectomy patients with rising serum PSA and may prove to have applications in earlier or later stages of disease. While [ 11 C]choline targets the prostate cancer cell and takes advantage of the technical virtues associated with PET, the short half-life of carbon-11 (t 1/2 ∼20 min) restricts the use of this radiotracer to major medical centers that can afford an on-site cyclotron. Lastly, 2-deoxy-2-[
18 F]fluoro-D-glucose PET has limited sensitivity for detection of metastatic lesions (with the exception of rare, poorly differentiated visceral lesions) and is confounded by accumulated signal in the urinary collecting system. An effective radiotracer for prostate cancer should detect both soft tissue and bony lesions, produce emissions compatible with PET for optimal resolution of disease foci, have a short radioactive and biological half-life to limit absorbed dose to the patient, and be widely available. Surveying the literature, we hypothesized that [
68 Ga]citrate could satisfy these conditions. First, [
67 Ga]citrate, an iron mimetic in vivo, has a longstanding history as an oncologic imaging agent, most notably for lymphoma, but also for certain solid tumors [3] . Among solid tumors, prostate cancer was disclosed in one report to harbor avidity for [ 67 Ga]citrate [4] . [
68 Ga]citrate also behaves as an iron mimetic in vivo, suggesting it may also target prostate cancer lesions. Additionally, [
68 Ga]citrate satisfies the aforementioned technical considerations, as it is compatible with PET, it clears quickly from the serum after binding to apo-transferrin, it has a short half-life (t 1/2 ∼68 min), and gallium-68 is produced as a chloride salt from a commercial benchtop 68 Ge/ 68 Ga generator rather than a cyclotron [5] . There is also a reasonable biological justification to argue for detecting prostate cancer with [
68 Ga]citrate. Since gallium-68 binds to transferrin (Tf) in situ, the uptake of this radiotracer in tumors is a measurement of biologically active transferrin receptor (TFRC) [6] 
Materials and Methods

Patient Selection
All patients had histologic evidence of prostate cancer with castration-resistant disease by PCWG2 criteria [9] . Patients were required to have undergone standard clinical staging scans including a CT of the abdomen and pelvis with intravenous contrast and nuclear medicine bone scan ( 
PET Imaging Protocol
All studies were performed on a SIGNA PET/MR scanner (GE Healthcare, Waukesha, WI). Patients were scanned after intravenous administration of [
68 Ga]citrate. Three-dimensional PET data were acquired in list-mode with a 4-to 8-min emission scan per bed for 6 bed stations. PET had 600 mm transaxial field of view (FOV) and 250 mm axial FOV. PET images were reconstructed with matrix size 128 × 128, 16 subsets and 4 iterations of time-of-flight enabled 3D ordered subset expectation maximization (TOF-3D-OSEM) algorithm, 8 mm full-width at half-maximum in-plane Gaussian post-reconstruction filter with a heavy z-axis filter as defined by the scanner manufacturer. Attenuation correction for PET reconstruction was performed using a MR-based attenuation correction (MRAC) technique provided by the scanner manufacturer.
Full-body MR examination was performed without IV contrast. MRAC, 3D dual-echo, spoiled gradient echo sequence with twoecho based Dixon fat-water, and axial T1 single-shot fast spin echo MR sequences were performed at each bed using the body surface coil.
Image Analysis
Maximum intensity projection (MIP), axial, coronal, and sagittal reconstructions, and PET/MR fused images were reviewed on an Advantage Windows Workstation (AW, Waukesha, WI). First, images were scored qualitatively for the presence of abnormal uptake by two experienced nuclear physicians (S.C.B. and C.M.A.) on a score of 1 to 3, based on the following scoring scale:
1 No lesions seen 2 Fair, lesions seen, but noise/artifact-limited evaluated 3 Adequate, lesions easily seen and assessed Next, PET images were evaluated by a ABNM trained nuclear medicine physician with over 8 years of experience (S.C.B., C.M.A.) and scored for the presence of PET-avid lesions. Lesions were considered PET positive if uptake was focal, greater than the adjacent background soft tissue, and not in an expected physiologic structure such as the urinary bladder, vessels, or salivary glands.
For semi-quantitative analysis, a volume of interest (VOI) was manually drawn around PET-avid lesions. The maximum standardized uptake value (SUV max ) and mean standardized uptake value (SUV mean ) were recorded. The location of abnormal radiotracer uptake was compared to CT and bone scan. Additionally, SUV mean and SUV max were recorded in the liver, paraspinous soft tissues, bone (right sacrum), and mediastinal blood pool.
CT images were reviewed by an experienced, fellowship trained abdominal imaging radiologist with over 10 years of experience (S.C.B.) for the presence of metastases. Lymph nodes measuring ≥8 mm short axis in the iliac chain and ≥10 mm short axis for the remainder of the abdominal and thoracic lymph nodes were used to define positive involvement by CT [10] . For non-nodal soft tissue lesions, measurements were recorded in long axis and considered positive if greater than 1 cm or clearly new from prior examinations when available. Nuclear medicine bone scans were reviewed by a nuclear medicine physician with over 10 years of experience (S.C.B., C.M.A.) and recorded the location of abnormal uptake.
Results
Eight patients were enrolled into this pilot study. The median age was 69 years old (59 to 79 years). All patients had castration-resistant prostate cancer metastatic to the bone, and a subset had additional sites of disease including the lymph nodes (N = 4) and the liver (N = 1). Baseline patient characteristics are summarized in Table 1 . 68 Ga]citrate and imaged at 180 and 210 min, respectively. Although tumor uptake in skeletal lesions and in one liver metastasis was clear, the overall quality of the scans was still poorly scored. To further increase the signalto-noise ratio, patient 4 was injected with a larger dose (∼260 MBq) of [
68 Ga]citrate and imaged at 225 min post injection. Two sclerotic bone lesions in the left femur were clearly resolved at 225 min, and the image quality was scored as Badequate^ (Fig. 1a) . These lesions were also active on the bone scan (Fig. 1b) . Four additional patients (patient 5-8) were scanned using the same parameters. There was clear evidence of tumor uptake of [
68 Ga]citrate in at least one lesion per patient, and all scans were scored as at least Bfair^( Table 3 and Supplemental Table 1 ; all imaging data are available upon request).
In this 8 patient cohort, a total of 96 lesions were detected with standard imaging scans, of which 84 were osseous and 12 were soft tissue (2 liver, 1 pleural, 9 lymph nodes). Four (3) anal uptake (SUV max = 3). There were a total of 12 soft tissue metastases seen on CT imaging, of which 4 were PET positive, and 8 were PET negative. Of the 4 PET positive lesions, 1 was hepatic and 3 were lymph nodes (Fig. 2) . The average SUV max of the soft tissue metastases was 8 (SD = 2.13, range 5.8 to 10.8). All of the lesions had a CT correlate with an average size of 1.8 cm (SD = 1.3, range 1 to 3.8). Of the 8 PET negative lesions, 6 were lymph node, 1 liver and 1 pleural with average CT size of 1.8 cm (SD = 0.5, range 1.3 to 2.6 cm). Finally, the average SUV max of all soft tissue and osseous metastases from patients 4-8 was statistically greater than that of the liver, muscle, and bone (Fig. 3b) . Blood pool activity was not statistically lower than the SUV max of soft tissue or bony metastases (P 9 0.01).
Discussion
In this study, we demonstrate that PET with [
68 Ga]citrate can resolve soft tissue and bony metastatic prostate cancer lesions. Our data suggests that ≥210 MBq of [
68 Ga]citrate and ≥210 min of imaging time post injection, combined with a modern high-sensitivity PET scanner, are required for adequate quality images. At these thresholds, [
68 Ga]citrate tumor uptake was generally congruent with lesion assignment by CT, MRI, and bone scan and SUV max values for tumor lesions were consistently higher than that observed in TFRC-expressing normal tissues like the muscle, liver, and bone. Lastly, our data shows that [
68 Ga]citrate can detect prostate cancer embedded within historically challenging microenvironments like the liver and lymph nodes. These data suggest that [
68 Ga]citrate may have utility in detecting early disease within pelvic lymph nodes, and assessing visceral tumor burden in advanced prostate cancer.
Despite the short half-life of gallium-68, we found that tumor imaging is possible using a relatively modest dose within 4 h post injection using increasingly available highsensitivity PET scanners. While noteworthy, this finding is consistent with previous studies of F-18 labeled Tf in primates. Indeed, Eckelman and colleagues showed evidence of specific uptake of [ 18 F]Tf in healthy baboon livers within 30 min post injection [11, 12] . Together, these observations underscore the unusually rapid delivery of Tf from the blood to peripheral tissues with biologically active TFRC, and provide a potential mechanistic rationale for our data.
Although [ 68 Ga]citrate resolved many metastatic prostate cancer lesions, approximately 25 % of lesions detected by 99m Tc]MDP scan shows the corresponding skeletal tumor burden. We are currently working to understand the basis for these observations. Because the blood pool activity was still significant using conditions that successfully highlight metastases, our leading hypothesis is that some prostate cancer metastases score as false negatives due to insufficient access to the radiotracer. We are currently testing this hypothesis more systematically. One additional consideration is that the undetected lesions may represent the minority of prostate cancer that does not harbor hyperactive MYC or PI3K signaling. Additionally, we observed low radiotracer uptake in the three areas that were felt to be inflammation, two related to osteoarthritis and one to proctitis. Overall, there were fewer areas of uptake attributable to osteoarthritis on [
68 Ga]citrate PET than standard radionuclide bone scan. The true sensitivity and specificity
of [
68 Ga]citrate PET in patients with concurrent chronic inflammatory conditions will require further prospective evaluation.
There are several limitations to our study. First, it was limited by the small cohort size (n = 8) as this was a proof of concept study. Additionally, the lack of pathologic confirmation and long-term follow up limits the assessment of false positive and negative findings. Therefore, larger scale studies as well as studies paired with biopsies and clinical follow up are warranted.
Many 18 F]fluoro-5-alpha-dihydrotestosterone cannot be used to detect prostate cancer in pre-castrate settings (abundant intratumoral androgens out-compete the radiotracer for androgen receptor binding), and this tool cannot be used to detect the growing percentage of androgen receptor-null, neuroendocrine like disease that emerges in castrationresistant prostate cancer [22] . Antibodies and ligands to PSMA also will not detect neuroendocrine prostate cancer, though they may be very useful to detect micrometastases in early disease or measure the effects of antiandrogen therapy [23, 24] . Some studies with [
68 Ga]HBED-CC have suggested PSMA PET outperforms both conventional imaging and [
18 F]choline in the detection of recurrent subclinical disease [25, 26] . While PSMA imaging is clearly promising, further work is needed to determine exactly where it and other agents fit in the prostate cancer treatment algorithm. Fig. 2 68 Ga-citrate demarcates soft tissue lesions. a PET/ MR and MR slices highlighting a necrotic liver metastasis from patient 3. The SUV max of the liver metastasis was 5.2, above the blood pool (3.8), normal liver (3.5), muscle (1.2), and bone (2.2). b PET/MR and MR slices highlighting a supraclavicular lymph node metastasis from patient 8. The SUV max was 10.8, above the blood pool (5.7), normal liver (4.3), muscle (2.0), and bone (1.9). 
Conclusions
In this study, we establish that prostate cancer metastases can be visualized with [
68 Ga]citrate. Preliminary guidelines were defined for minimum dose and time post injection. Further study is warranted to determine the conditions required to visualize all metastases, or to establish more robustly if some lesions are inherently quiescent for this radiotracer. Moreover, the patient cohort will be increased to corroborate the findings of this feasibility study.
